Huaren Pharmaceutical Co., Ltd. (300110.SZ)
CNY 2.9
(3.2%)
CNY 2.9
(3.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 188.06 Million CNY | 4.03% |
| 2022 | 180.77 Million CNY | 38.63% |
| 2021 | 130.4 Million CNY | 37.81% |
| 2020 | 94.62 Million CNY | 124.94% |
| 2019 | 42.06 Million CNY | 8.43% |
| 2018 | 38.79 Million CNY | 3.36% |
| 2017 | 37.53 Million CNY | 56.75% |
| 2016 | 23.94 Million CNY | 4.4% |
| 2015 | 22.93 Million CNY | -59.15% |
| 2014 | 56.15 Million CNY | -53.79% |
| 2013 | 121.51 Million CNY | 25.81% |
| 2012 | 96.58 Million CNY | 10.31% |
| 2011 | 87.56 Million CNY | 14.73% |
| 2010 | 76.31 Million CNY | 25.59% |
| 2009 | 60.76 Million CNY | 30.88% |
| 2008 | 46.43 Million CNY | 36.0% |
| 2007 | 34.14 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 22.39 Million CNY | -55.94% |
| 2024 Q3 | 22.31 Million CNY | -0.32% |
| 2024 Q1 | 50.82 Million CNY | -0.31% |
| 2023 Q3 | 54.8 Million CNY | 33.08% |
| 2023 Q4 | 50.97 Million CNY | -6.97% |
| 2023 FY | 188.06 Million CNY | 4.03% |
| 2023 Q1 | 41.1 Million CNY | -28.65% |
| 2023 Q2 | 41.17 Million CNY | 0.19% |
| 2022 FY | 180.77 Million CNY | 38.63% |
| 2022 Q2 | 49.06 Million CNY | 95.94% |
| 2022 Q3 | 49.1 Million CNY | 0.1% |
| 2022 Q4 | 57.6 Million CNY | 17.3% |
| 2022 Q1 | 25.03 Million CNY | 90.98% |
| 2021 Q3 | 43.78 Million CNY | -10.06% |
| 2021 FY | 130.4 Million CNY | 37.81% |
| 2021 Q1 | 24.82 Million CNY | -38.74% |
| 2021 Q2 | 48.68 Million CNY | 96.09% |
| 2021 Q4 | 13.11 Million CNY | -70.05% |
| 2020 FY | 94.62 Million CNY | 124.94% |
| 2020 Q3 | 18.98 Million CNY | -35.09% |
| 2020 Q4 | 40.52 Million CNY | 113.47% |
| 2020 Q1 | 5.86 Million CNY | -64.58% |
| 2020 Q2 | 29.24 Million CNY | 398.64% |
| 2019 Q3 | 12.53 Million CNY | 55.63% |
| 2019 FY | 42.06 Million CNY | 8.43% |
| 2019 Q1 | 4.9 Million CNY | -55.14% |
| 2019 Q2 | 8.05 Million CNY | 64.17% |
| 2019 Q4 | 16.56 Million CNY | 32.07% |
| 2018 Q1 | 2.26 Million CNY | -84.24% |
| 2018 FY | 38.79 Million CNY | 3.36% |
| 2018 Q4 | 10.94 Million CNY | -4.4% |
| 2018 Q2 | 14.14 Million CNY | 524.16% |
| 2018 Q3 | 11.44 Million CNY | -19.08% |
| 2017 Q3 | 14.69 Million CNY | 240.5% |
| 2017 Q4 | 14.37 Million CNY | -2.16% |
| 2017 FY | 37.53 Million CNY | 56.75% |
| 2017 Q2 | 4.31 Million CNY | 3.96% |
| 2017 Q1 | 4.15 Million CNY | -58.07% |
| 2016 Q4 | 9.89 Million CNY | -9.9% |
| 2016 Q1 | 2.38 Million CNY | 131.05% |
| 2016 Q2 | 672.48 Thousand CNY | -71.85% |
| 2016 Q3 | 10.98 Million CNY | 1533.7% |
| 2016 FY | 23.94 Million CNY | 4.4% |
| 2015 FY | 22.93 Million CNY | -59.15% |
| 2015 Q2 | 5.83 Million CNY | -61.03% |
| 2015 Q3 | 9.82 Million CNY | 68.47% |
| 2015 Q4 | -7.69 Million CNY | -178.28% |
| 2015 Q1 | 14.96 Million CNY | 1097.1% |
| 2014 Q3 | 25.43 Million CNY | 623.57% |
| 2014 Q4 | -1.5 Million CNY | -105.9% |
| 2014 Q1 | 28.7 Million CNY | -25.9% |
| 2014 Q2 | 3.51 Million CNY | -87.75% |
| 2014 FY | 56.15 Million CNY | -53.79% |
| 2013 Q3 | 33.74 Million CNY | 43.55% |
| 2013 Q1 | 25.53 Million CNY | 5.21% |
| 2013 Q4 | 38.73 Million CNY | 14.79% |
| 2013 FY | 121.51 Million CNY | 25.81% |
| 2013 Q2 | 23.5 Million CNY | -7.92% |
| 2012 Q2 | 24.9 Million CNY | 28.34% |
| 2012 Q4 | 24.26 Million CNY | -13.34% |
| 2012 Q1 | 19.4 Million CNY | -30.9% |
| 2012 FY | 96.58 Million CNY | 10.31% |
| 2012 Q3 | 28 Million CNY | 12.42% |
| 2011 FY | 87.56 Million CNY | 14.73% |
| 2011 Q3 | 21.12 Million CNY | 8.6% |
| 2011 Q2 | 19.45 Million CNY | 2.97% |
| 2011 Q4 | 28.08 Million CNY | 32.94% |
| 2011 Q1 | 18.89 Million CNY | -24.62% |
| 2010 FY | 76.31 Million CNY | 25.59% |
| 2010 Q1 | 14.14 Million CNY | 4.03% |
| 2010 Q2 | 20.54 Million CNY | 45.24% |
| 2010 Q3 | 16.57 Million CNY | -19.3% |
| 2010 Q4 | 25.06 Million CNY | 51.2% |
| 2009 Q3 | 20.14 Million CNY | 0.0% |
| 2009 Q4 | 13.59 Million CNY | -32.53% |
| 2009 FY | 60.76 Million CNY | 30.88% |
| 2008 FY | 46.43 Million CNY | 36.0% |
| 2007 FY | 34.14 Million CNY | 0.0% |